Can-Fite BioPharma Ltd. (TASE:CFBI) today reported success in the Phase I/II clinical trial of its CF102 drug for the treatment of liver cancer (hepatocellular carcinoma or HCC). The safety and efficacy trial met all its primary and secondary endpoints.
In a separate Phase I/II clinical trial of CF102 for the treatment of hepatitis C, the drug met its main safety and concentration in the blood targets.
The liver cancer trial included 18 patients at the Rabin Medical Center in Petah Tikva. Most of the patients were previously treated with Nexavar, the only commercially available treatment, made by Bayer AG (DAX: BAYN). The median survival time was 7.8 months, a significant figure, since CF103 was given as a second line of treatment for most of the patients. It was also given to patients with advanced cases of the disease, and their median survival time was 9.4 months - a period never reported by any commercially available drug or drug under development.
Can-Fite CEO Pnina Fishman said that the company would continue development of CF102 as the primary treatment for liver cancer, and that it would also monitor levels of hepatitis C in the patients.
Can-Fite's share price rose 10% by midday to NIS 0.507, giving a market cap of NIS 122 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 3, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012